Wikipedia -WSS

Wikipedia

author：explore 2025-09-06 04:14:30 - browse：14

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Gene therapy denied for Afghan refugee whose father aided U.S.

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

leisure time

Wikipedia

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

JPM pitch from hospitals? Revenue streams outside of patient care

Bright Health sells Medicare Advantage business to Molina

Arena BioWorks launches in Cambridge to speed drug discovery

Trump demands the U.S. pay no more for drugs than other countries … again

How AI can help patients find reliable information about doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How AI can help patients find reliable information about doctors

New air purifier tech could be key to improving indoor air quality

STAT Summit: The economic case for universal basic health care

hotspot

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Is there really a nursing shortage in the U.S.?

STAT Readout Newsletter: Biotech news today

Merck to acquire Harpoon Therapeutics for $680 million

Profiling embryos to choose those with higher IQs is almost a reality

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

leisure time

hotspot

Wikipedia

leisure time